Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent
The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.
OptraHealth sues Invitae over genetic testing chatbot
OptraHealth has filed a patent infringement lawsuit against Invitae that centres on the latter’s Gia chatbot that offers genetic testing and advice.
NIH COVID-19 deal broadens access for poorer nations
The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.
USPTO urges Vidal review of Arthrex petition
The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.
Roche and Bluebird settle ‘Spark’ TM suit
Roche subsidiary Spark Therapeutics has settled a lawsuit with rival gene-therapy company Bluebird Bio, which it had accused of infringing its “Spark” trademarks when marketing treatment for sickle-cell disease.
Natera accuses CareDx of infringing DNA testing patents
Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Emcure says court should dismiss COVID vaccine secrets suit
Indian pharmaceutical company Emcure has asked a Washington court to toss a lawsuit accusing the company of stealing trade secrets related to a COVID-19 vaccine.
Beckman Coulter loses late-stage bid to pause infringement proceedings
The US District Court for the District of Delaware has denied a motion from Beckman Coulter to stay an patent infringement lawsuit involving Sysmex Corporation until parallel proceedings at the US Court of Appeals for the Federal Circuit are concluded.
BMS says Hengrui’s Abraxane infringes
A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.
Novartis' Gilenya patent survives invalidity bid
Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.
